a r t i c l e s
The repair process after tissue injury involves a regeneration phase, in which injured cells are replaced by cells of the same lineage 1 , and a fibrotic phase, in which connective tissues replace normal parenchymal tissue 2 . Repair can either leave no lasting evidence of damage or can result in fibrotic lesions that can lead to progressive organ dysfunction. In the kidney, fibrosis is responsible for chronic progressive kidney failure, which is present in approximately 8-10% of individuals in the developed world 3, 4 . AKI can result in incomplete repair and persistent tubulointerstitial inflammation, with proliferation of fibroblasts and excessive deposition of extracellular matrix, a common feature of many kinds of kidney diseases and a primary determinant of progression to end-stage renal failure 5, 6 . The cellular mechanisms that facilitate tubulointerstitial fibrosis after injury remain poorly defined. Whereas tubular epithelial cells have been proposed to have an active role in the progression of fibrosis via epithelial-to-mesenchymal transformation [7] [8] [9] , recent data indicate that fibrosis can occur in the absence of this cellular transformation process 1, 10 . It also has been proposed that profibrotic factors such as transforming growth factor-β1 (TGF-β1) and connective tissue growth factor (CTGF) are upregulated in the tubulointerstitial area upon injury, leading to kidney fibrosis 11, 12 . Currently, however, it is not clear how and to what extent tubular cells contribute to tissue fibrosis.
The potent capacity of tubular epithelial cells to proliferate and replace lost cells is crucial for repair and enables recovery from many ischemic or toxic insults 1, 13 . Enhanced expression of cell cycle regulatory proteins such as p53, p21 and p16 in renal proximal tubular cells has been implicated in repair in ischemic and cisplatin-toxic AKI animal models, deteriorating renal transplants and chronic-diseased native kidneys in human beings [14] [15] [16] [17] . There is increasing evidence that modulating these cell cycle regulatory proteins can affect the severity of acute ischemic or cisplatin-induced toxic kidney injury [18] [19] [20] . Cell cycle arrest or dysregulation, however, has not been linked to fibrosis. Here we characterized the cell cycle profile of tubular epithelial cells in vivo at various times after an acute insult in five AKI models: moderate reversible ischemia reperfusion injury (IRI), severe IRI, unilateral IRI, acute aristolochic acid toxic nephropathy (AAN) and unilateral ureteral obstruction (UUO). These models reflect three of the most common causes for AKI seen in humans: ischemia, toxic exposure and obstruction. Each is characterized by acute tubular injury and interstitial inflammation but have distinct long-term outcomes. The development of fibrosis and the production of profibrotic cytokines in each of the AKI models correlated with the arrest of proximal tubule epithelial cells in G2/M. Abrogating the G2/M arrest markedly reduced fibrosis and cytokine production, consistent with a direct role for cell cycle dysregulation in the progression of AKI to chronic kidney disease.
RESULTS

Different fibrotic outcomes in various AKI models
To test the effect of injury on initiation and development of fibrosis in the kidney, we studied five AKI mouse models. We measured serum creatinine to evaluate renal dysfunction, as it is a measure of glomerular filtration rate. The normal serum creatinine concentration in mice is below 0.2 mg dl −1 . The moderate IRI, severe IRI and AAN mice showed abrupt renal dysfunction after ischemia or aristolochic acid injection, with serum creatinine peaking at 1.50 ± 0.52 mg dl − Fibrosis is responsible for chronic progressive kidney failure, which is present in a large number of adults in the developed world. It is increasingly appreciated that acute kidney injury (AKI), resulting in aberrant incomplete repair, is a major contributor to chronic fibrotic kidney disease. The mechanism that triggers the fibrogenic response after injury is not well understood. In ischemic, toxic and obstructive models of AKI, we demonstrate a causal association between epithelial cell cycle G2/M arrest and a fibrotic outcome. G2/M-arrested proximal tubular cells activate c-jun NH 2 -terminal kinase (JNK) signaling, which acts to upregulate profibrotic cytokine production. Treatment with a JNK inhibitor, or bypassing the G2/M arrest by administration of a p53 inhibitor or the removal of the contralateral kidney, rescues fibrosis in the unilateral ischemic injured kidney. Hence, epithelial cell cycle arrest at G2/M and its subsequent downstream signaling are hitherto unrecognized therapeutic targets for the prevention of fibrosis and interruption of the accelerated progression of kidney disease.
1.02 ± 0.21 mg dl −1 , respectively (Fig. 1a) . In the moderate IRI model, serum creatinine decreased sharply after the peak on day 1 and returned to normal levels by day 7 (Fig. 1a) . In the severe IRI and AAN mouse models, however, the decrease in serum creatinine was delayed, and serum creatinine remained above normal levels for at least 42 d after injury (P < 0.01, Fig. 1a ) and did not return to baseline for the duration of the study. In the two unilateral AKI models, the unilateral IRI and UUO models, the serum creatinine concentration did not increase significantly because of compensation by the normal contralateral kidney (Fig. 1a) .
In all models other than moderate IRI, histological examination revealed interstitial fibrosis (Fig. 1b) , which was confirmed by tissue collagen quantification (Fig. 1c) . Immunostaining of markers associated with fibrosis including collagen IV, α-smooth muscle actin (α-SMA) (Fig. 1d) and collagen I together with morphometric quantification (Fig. 1e) revealed robust protein accumulation in the interstitial area, demonstrating the chronic fate of the kidney in the four AKI models.
Tubular G2/M arrest characterizes profibrotic AKI models
The cellular hallmark of kidney repair after AKI is a proliferative response of surviving tubular epithelial cells. In all of the AKI models, there was prominent renal tubule proliferation after acute injury. The cell cycle distribution in vivo during injury and recovery was characterized as a function of time in moderate IRI, unilateral IRI, AAN, severe IRI and UUO models (Fig. 2a-c) .
To analyze the cell cycle distribution of proximal tubular epithelial cells in vivo, we used several approaches. We complemented immunohistochemistry staining of cell cycle markers in vivo with analysis of cell cycle markers in isolated proximal tubules, and we compared chromatin characteristics in vivo with chromatin pattern at various stages of the cell cycle in vitro. We labeled proliferating cells (G1, S, G2 and M phase) in vivo with Ki-67 specific antibody 21 (Fig. 2a) , identified cells in S phase by the uptake of BrdU, detected by staining with antibody to BrdU 21 ( Fig. 2a) and detected cells in G2/M phase by quantifying the number of tubular cells with phosphorylation of histone H3 at Ser10 (p-H3) through staining with a phosphorylationspecific antibody 22 (Fig. 2a) . As demonstrated by flow cytometry analysis, p-H3 was also a good marker for the G2/M phase of the cell cycle in vitro (Supplementary Fig. 1a) . Immunostaining of p-H3 in cells in vitro ( Supplementary Fig. 1a,b ) and in tissues in vivo (Supplementary Fig. 1c ) revealed the same staining patterns in the G2 and M stages of the cell cycle. We calculated the number of cells in G1 phase by subtracting the number of cells in S phase (BrdU positive) and G2/M phase (p-H3 positive) from the total number of proliferating cells (Ki-67 positive) and expressed the proportion of cells in each phase as the percentage of total proliferating cells (Fig. 2b,c) .
The moderate IRI mice had transient cell cycle changes in proximal tubular cells in the outer medulla (Fig. 2a,b) , with a high proportion of S phase (65.2 ± 6.8%) on day 1, reflecting an active repair response. The percentage of cells in G2/M phase increased from approximately 15% on day 1 to 30% on day 5 (Fig. 2b) . After day 7, the cell cycle distribution of proliferating tubular cells reached a relatively stable profile, with approximately 15-20% in S phase and 15-20% in G2/M phase (Fig. 2b) . The unilateral IRI model mice showed a similar initial proximal tubular proliferation curve when compared to the moderate IRI mice (Fig. 2a,b) ; however, the percentage of cells in G2/M phase increased to greater than 50% by day 5 and remained at a high level for the duration of observation (82.2% ± 10.9% on day 42, Fig. 2b) . In the AAN model, there was an increase in cortical proximal tubular cells in S phase, peaking at day 14, with a subsequent reduction in S phase cells to 15-20% after 28 d (Fig. 2a,b) . Similar to the unilateral IRI model, there was an obvious and persistent higher number of cells in G2/M phase beginning from day 5 and remaining at high levels during the entire repair phase (56.6% ± 5.9% on day 42, Fig. 2b) . Thus, in the unilateral IRI and AAN AKI models, which both resulted in fibrosis, the common feature was the increase in a persistent proximal tubule G2/M population ( Fig. 2b,c) . The findings in the UUO and severe bilateral IRI were similar to the unilateral IRI and AAN models, with G2/M populations accumulating from day 3 through day 28 or day 14, respectively ( Fig. 2c) . The cells that co-stained with antibodies to Ki-67 and p-H3 in kidneys examined 7 d after unilateral IRI were tubular cells (Fig. 2d) . The co-staining reflected a much higher proportion of cells in the G2/M phase of the cycling population in unilateral IRI when compared to moderate IRI. By co-staining of proliferative markers and proximal tubular markers (lotus lectin 23 (data not shown) and Kim-1 24 , Fig. 2e ), we found that more than 95% of the proliferating tubular cells after acute injury from ischemia-reperfusion, aristolochic acid treatment or UUO were of proximal tubular origin. Accumulation of cells in G2/M in models of AKI associated with fibrosis was also confirmed by the increased cyclin B1 / cyclin D1 ratio, seen in severe IRI, unilateral IRI, AAN and UUO (Fig. 2f) .
Furthermore, we characterized the time-dependence of BrdU incorporation in AKI models (Fig. 2g,h) . We injected mice with BrdU to label cells in S phase and removed kidneys at 2, 4, 8 and 12 h after BrdU injection (Fig. 2g) . At later time points, there were very few BrdU-positive cells in the moderate IRI kidney that co-stained with p-H3 (Fig. 2g,h ), indicating that cells that labeled with BrdU had progressed through the cell cycle and past the G2/M phase. By contrast, in the profibrotic kidney models (AAN and UUO), most of the tubular cells that took up BrdU were still in G2/M phase of the cell cycle 4, 8 and 12 h later, indicating that the increase in number of tubular cells in G2/M in the profibrotic AKI models is due to the elongation of the G2/M phase in these cells (Fig. 2g,h ). We did not detect G2/M arrest in the interstitial cells in any of the AKI models (data not shown). Thus, all AKI mouse models where prominent fibrosis developed (unilateral IRI, severe IRI, AAN and UUO), are characterized by arrest of proximal tubular epithelial cells in the G2/M phase of the cell cycle. To verify whether G2 or M phase arrest was more characteristic of the observed fibrotic phenotype, we used the characteristics of p-H3 staining to distinguish G2 from prophase and late mitotic phases 22, 25 . We found that about 95% of tubular cells were arrested in G2 phase, as observed by a typical G2 phase foci-like staining of p-H3 (Supplementary Fig. 1c ).
G2/M arrest results in upregulation of profibrogenic growth factors
To investigate whether and how proximal tubular epithelial cell arrest in G2/M is involved in fibrogenesis, we complemented studies in vivo with evaluation of the effects of aristolochic acid in vitro on several proximal tubular cell lines: human HK-2 cells, pig LLC-PK1 cells and rat IRPTC cells. In each of the cell lines, aristolochic acid (5 µg ml −1 ) treatment for 48 h resulted in a marked increase in the percentage of cells in G2/M (Fig. 3a) and a marked upregulation of messenger RNA expression of fibrogenic growth factors encoding a r t i c l e s TGF-β1 and CTGF (Fig. 3b) . In addition, aristolochic acid resulted in activation of the COL4A1 gene (encoding collagen-4α1) in HK-2 cells and IRPTC cells and COL1A1 (encoding collagen-1α1) in HK-2 cells (Fig. 3b) . The protein amounts of TGF-β1 and CTGF were also increased in the supernatant of aristolochic acid -treated HK-2 cells by factors of 2.01 ± 0.23 (P < 0.01) and 39.94 ± 5.69 (P < 0.001), respectively (Fig. 3c) .
To determine whether the G2/M cells were responsible for the generation of profibrotic factors, we isolated G0/G1 phase and G2/M phase cells by cell sorting using Hoechst staining. In normal cultured HK-2 cells, the G2/M phase cells had higher mRNA levels of COL4A1 and ACTA2 (encoding α-smooth muscle actin, α-SMA) than did cells in the G0/G1 phase, whereas the levels of TGFB1 and CTGF were similar between the cells in the two phases of cell cycle (Fig. 3d) . After aristolochic acid treatment for 48 h, HK-2 cells in both G0/G1 and G2/M phases showed a higher level of TGFB1 gene production compared with the normally growing cells in the corresponding cell cycle phases (by factors of 2.01 ± 0.66 and 3.33 ± 0.48, respectively, P < 0.05) (Fig. 3d) . HK-2 cells arrested in G2/M phase secondary to aristolochic acid exposure had elevated CTGF mRNA levels (6.0 ± 1.11 fold compared with normal cycling G2/M cells, P < 0.01) (Fig. 3d) . HK-2 cells arrested in G2/M phase also showed increased levels of COL4A1 and ACTA2 gene production compared with G0/G1 phase cells in normal culture or after aristolochic acid treatment, but these levels were no higher than the normally cycling HK-2 cells in G2/M (Fig. 3d) . Providing further evidence of a causal relationship between the profibrotic factors generated by the G2/M-arrested cells and fibrosis, we found that the conditioned medium from aristolochic acid-treated HK-2 cells enhanced proliferation (Fig. 3e) and collagen production (Fig. 3f) of fibroblasts in vitro.
We determined in vivo mRNA levels of Tgfb1, Ctgf, Col4a1 and Col1a1 in injured mouse kidney tissue of all models of AKI. Each of the AKI models showed elevated mRNA levels of these four profibrogenic factors soon after the initiation of the injury (Fig. 3g) . In the moderate IRI model, where fibrosis did not occur, the mRNA levels of these fibrogenic genes fell to baseline within the first 1 to 2 weeks after the acute insult, whereas in the other four AKI models, characterized by the development of fibrosis, elevated gene expression levels were sustained for 42 d or for the duration of the study (14 d in the case of UUO) (Fig. 3g) .
In addition, TGF-β1 and CTGF protein production from tubules isolated from moderate IRI and aristolochic acid-treated mice were increased, as determined by western blot analysis, particularly in the aristolochic acid-treated group (Fig. 3h) . TGF-β1 and CTGF co-localized with p-H3-positive tubular nuclei in vivo (Fig. 3i) . Thus, profibrogenic growth factors are upregulated in G2/M-arrested tubular cells both in vitro and in vivo, and the factors produced in vitro can stimulate the proliferation and collagen production of fibroblasts. Tubular cell apoptosis has been associated with fibrosis. In the present study, all of the AKI models, whether resulting in fibrosis or not, showed a substantial increase in tubular cell apoptosis after injury (Supplementary Fig. 2a) . Furthermore, there were no differences in total integrated amount of apoptosis in the nonfibrotic moderate IRI model and the profibrotic AAN model over 42 d of observation after injury (Supplementary Fig. 2b) . Over the first 14 d, there was more apoptosis in moderate IRI than in the aristolochic acid-treated mice, yet there was much more profibrogenic gene expression and protein production, as well as increased amounts of fibrosis, in the aristolochic acid-treated mice. The density of tubular cells in vivo supports the conclusion that G2/M arrest of epithelial cells affects the epithelial cell proliferating efficiency after an acute injury insult (Supplementary Fig. 2c ).
In vitro, aristolochic acid, at a dose of 5 µg ml −1 , upregulated profibrotic genes but did not cause enhanced apoptosis in HK-2 cells (Supplementary Fig. 2d ). These data in vivo and in vitro suggest that epithelial G2/M arrest results in fibrosis independent of effects on apoptosis. The reduced number of epithelial cells seen in the injury models associated with fibrosis is therefore explained by cell cycle arrest rather than an increase in apoptosis.
Reversal of G2/M arrest rescues the fibrogenic effect G2/M checkpoint arrest occurs primarily through the activation of protein kinases Chk1 and Chk2, which are downstream of the ATM-ATR (ataxia telangiectasia, mutated-ATM and Rad3-related) pathway 26, 27 . Although it has been well established that the ATM-ATR pathway can be activated by DNA damage, activation also occurs under non DNA-damaging conditions, such as hypoxia and reoxygenation 28 . We detected distinct ATM activation in the tubular cells in severe IRI, unilateral IRI, AAN and UUO mice through immunostaining of phosphorylated ATM ser1981 (p-ATM) ( Fig. 4a and Supplementary Fig. 3a) . There was no detectable p-ATR by either immunostaining or western blotting in control or kidney injury models (data not shown).
In aristolochic acid-treated HK-2 cells, activation of the ATM pathway was also Fig. 3b ) and western blot analysis of p-ATM, p-Chk2 and p-p53 (Fig. 4b) . Incubating HK-2 cells with KU-55933 (an ATM inhibitor) 29 reduced the fraction of cells in G2/M arrest by ~50% (Fig. 4c) . Associated with the reduction in G2/M arrested cells, the mRNA levels of TGFB1, CTGF, COL4A1 and COL1A1 were also downregulated by ~50% (Fig. 4c) . We observed a similar rescue effect in LLC-PK1 cells and IRPTC cells treated with KU-55933 and aristolochic acid (Fig. 4c) .
a r t i c l e s evident, as determined by immunostaining of p-ATM (Supplementary
We further confirmed the effect of ATM inhibition in reducing G2/M arrest and decreasing profibrogenic factor production by reducing ATM expression with shRNA in HK-2 cells and LLC-PK1 cells (Fig. 4d  and Supplementary Fig. 3c ). There were marked reductions in TGF-β1 and CTGF mRNA levels in both cell types when the we used ATM-specific shRNA to mitigate the effect of aristolochic acid on the number of cells in G2/M (Fig. 4d) .
To further evaluate whether there is a causal relationship between G2/M arrest and fibrosis, we designed two experimental mouse models to rescue G2/M arrest. Both experiments were performed in the unilateral IRI model, which normally results in the development of prominent fibrotic lesions (Fig. 1b-e) . One group of unilateral IRI mice was injected intraperitoneally with 2.2 mg per kg body weight of pifithrin-α (PIF-α), a p53 inhibitor 30 , on days 3 and 14 after surgery. We injected control mice with the same amount of the saline vehicle. Another group of unilateral IRI mice underwent nephrectomy of the healthy contralateral kidney 3 d after unilateral IRI surgery. Both PIF-α treatment and contralateral nephrectomy decreased the accumulation of G2/Marrested tubular cells by >50% and >60%, respectively, on day 10 after unilateral IRI (Fig. 4e) . The degree of increase of mRNA levels of profibrogenic genes and the degree of interstitial fibrosis were all markedly reduced by either treatment (Fig. 4f,g ). Given that we performed PIF-α injection or nephrectomy 3 d after unilateral IRI surgery, the severity of initial kidney injury was not affected by these treatments (by histological injury scoring, data not shown). Taken together, these data indicate that the development of fibrosis was markedly suppressed when the number of tubular epithelial cells arrested in G2/M was reduced in vivo.
As in the case of PIF-α treatment, at 42 d after unilateral IRI, the nephrectomy treatment group had much less fibrosis and less of an increase in kidney collagen content (Fig. 4g) . The fibrosis that did exist was localized in focal stripe-like distributions (Fig. 4g) . Although . 3d ).
Imposed prolonged G2/M arrest causes a profibrotic phenotype
To further establish that prolonged arrest at the G2/M boundary can result in a prominent profibrotic phenotype we adopted alternative strategies to induce G2/M arrest. When we administered R03306, a cyclin-dependent kinase-1 inhibitor known to induce a reversible G2/M transition defect 31 , to HK-2 and LLC-PK1 cells, the number of cells in G2/M increased to 30% at 24 h and ~55-71% at 48 h (Fig. 5a,b) . Profibrogenic gene expression was markedly increased at 48 h (Fig. 5b) . Through Hoechst staining and cell sorting, we isolated the G2/M phase HK-2 cells after treatment with R03306 for 48 h and compared gene expression with that in G0/G1 cells. We confirmed the G2/M phase cells to be the origin of profibrogenic gene expression (Fig. 5c) . After we washed out the R03306, the tubular cells were able to exit G2/M arrest, with a return of profibrogenic gene expression to close to baseline (Fig. 5b,c) .
We also used paclitaxel (Taxol), a microtubule stabilizing agent 32 , to induce progressive G2/M arrest. Low-dose (~50 nM-10 µM) paclitaxel treatment of HK-2 cells for 24 h caused prominent G2/M arrest (Fig. 5d) , with upregulation of mRNA expression of TGFB1, CTGF, COL4A1 and COL1A1 and increased CTGF protein secretion into the supernatant (Fig. 5e) . Paclitaxel administration (20 mg per kg body weight) in vivo at 1 and 4 d after ischemia-reperfusion to the moderate IRI mice caused a sustained increase in the number of renal tubular cells in the G2/M phase (Fig. 5f) and, as predicted, resulted in development of interstitial fibrosis (Fig. 5g) . To confirm that the observed phenotype was not the consequence of direct paclitaxel-induced tubular cell toxicity, we evaluated the serum creatinine concentration and the extent of tubular necrosis after paclitaxel administration. There were no differences in the peak serum creatinine concentration (Fig. 5h) or the degree of tubular necrosis (data not shown) between the moderate IRI and paclitaxel-treated moderate IRI mice.
JNK signaling mediates fibrogenic cytokine upregulation
Given the well-known effect of mitogen-activated protein kinases (MAPKs) in cell proliferation, apoptosis and fibrosis, we evaluated their involvement in the fibrogenic effect caused by G2/M arrest. After a r t i c l e s treatment of HK-2 cells with aristolochic acid, R03306 or paclitaxel, there was prominent activation of JNK signaling, with increased levels of p-JNK and p-c-jun, that coincided with periods when G2/M arrest was prominent (Fig. 6a) . We also found extracellular signal-regulated kinase (ERK) activation in HK-2 cells with each of the three treatments, but it occurred earlier than the onset of G2/M arrest (Fig. 6a) . The level of p-p38 was increased with aristolochic acid or RO3306 treatment but not with paclitaxel treatment (Fig. 6a) .
To investigate whether MAPKs might be mechanistically involved in G2//M arrest and profibrogenic gene production, we took advantage of three specific inhibitors, including SP600125, a pan-JNK inhibitor; SB203580, a p38 inhibitor; and U0216, a MEK inhibitor. Although none of these three inhibitors at various doses was able to rescue the G2/M arrest in HK-2 cells treated with aristolochic acid, R03306 or paclitaxel (Fig. 6b and data not shown) , SP600125 decreased the upregulation of mRNA levels of profibrogenic genes induced by aristolochic acid, R03306 or paclitaxel by ~40-80% (Fig. 6b) . The MEK inhibitor, by contrast, exacerbated the increase in profibrogenic gene upregulation (amplified by an extra fivefold), whereas the p38 inhibitor did not affect the gene activation in these conditions (data not shown). The secretion of CTGF by HK-2 cells treated with aristolochic acid, RO3306 or paclitaxel was decreased by ~75% in the presence of the JNK inhibitor (shown with aristolochic acid in Fig. 6c) . In addition, the increased proliferation and collagen production in fibroblasts triggered by conditioned medium from aristolochic acid-treated HK-2 cells were diminished by ~80% and ~60%, respectively when we also treated aristolochic acid-treated HK-2 cells with the JNK inhibitor (Fig. 6d,e) . Examination of kidney sections from the fibrotic AKI models revealed colocalization of JNK signaling activation markers (p-JNK and p-c-jun immunoreactivity) with p-H3-positive nuclei in all injury models (shown for the AAN model in Fig. 6f) . To test the role of JNK in the fibrotic response in vivo, we injected mice intraperitoneally with SP600125 (1 mg per day), starting at 7 d after unilateral IRI, after the acute injury phase was over, and continued the treatment until 28 d after surgery. We introduced the treatment at 7 d to avoid potential effects of the drug on the degree of acute injury, inflammation, cell proliferation and the onset of epithelial G2/M arrest in the unilateral IRI model (Fig. 2) . JNK inhibition in vivo reduced fibrosis (Fig. 6g,h ), kidney collagen content (Fig. 6h) and mRNA levels of Tgfb1, Ctgf, Col4a1 and Col1a1 in the unilateral IRI model (Fig. 6i) .
DISCUSSION
Fibrosis is a common event that leads to the derangement of tissue structure and irreversible loss of normal organ function. In the kidney, tubulointerstitial fibrosis is a poor prognostic indicator and represents a common final pathway in the progression to end-stage renal disease, irrespective of the initial cause. Acute kidney injury has been recognized as a major contributor to chronic and end-stage kidney disease 33 . A fundamental unanswered question in understanding the pathogenesis of kidney fibrosis is the nature of the molecular switch that differentiates renal tubular reparative from fibrotic responses to injury. Our results indicate that proximal tubular cells arrested in the G2/M stage of the cell cycle after injury produce profibrogenic growth factors that are capable of stimulating fibroblast proliferation and collagen production.
Here we characterized the time-dependent cell cycle progression in vivo in five models of acute kidney injury in the mouse. Through this analysis, we found a strong correlation between G2/M arrest in tubular cells and a fibrotic outcome. The profibrotic effects were greatly attenuated when we reduced the time spent in G2/M in vitro and in vivo, either by inhibition of the ATM pathway or by contralateral nephrectomy, another maneuver that facilitates movement out of the G2/M phase of the cell cycle.
Cell cycle analysis in vivo proved to be a predictive tool for determining the progression of kidney injury to either normal proximal tubule cell proliferation and epithelial repair or fibrosis. The ability to identify cell types, including nephron segment or nontubular cells, and cell cycle stage all resolved in time, provides the opportunity to study repair processes at cellular resolution. These observations identified the tubular cells as crucial participants in the fibrotic fate. The association in vitro and in vivo of G2/M arrest and production of profibrogenic growth factors from the tubular cells under a number of conditions where G2/M is altered independently provides additional evidence that tubular cells arrested in G2/M have a primary role in determining the fibrotic response.
The major factors investigated here and shown to be upregulated in the G2/M-arrested tubular cells were TGF-β1 and CTGF. TGF-β1 is a well-established principal driver of fibrosis via promotion of fibroblast proliferation, extracellular matrix synthesis and inhibition of collagenases in multiple organs 34, 35 . CTGF is a key downstream effector of profibrotic TGF-β1 activity. CTGF acts both in TGF-β1-independent and TGF-β1-dependent fashions and has proved to have key roles in the development of fibrosis in multiple organs, including the kidney [36] [37] [38] [39] .
There are a number of previous studies where findings can be re-interpreted as supportive of conclusions that proximal tubule G2/M arrest leads to fibrosis. Interpretations of cellular senescence and active cell cycle kinetics have focused previous analyses on cell cycle regulation at the restriction point that permits transition from G1 to S. These same regulators (for example, p53, p21 and p19INK) can all act during G2 to prevent mitotic progression after genotoxic stress 41 . For example, p53 has a key role at the G2 checkpoint that regulates the G2/M transition in response to stress and DNA damage 41 . p21 is a transcriptional target of p53 and also participates in the G2 checkpoint by inhibiting cyclindependent kinases 42 . Trp53 deficiency results in less kidney interstitial fibrosis in unilateral IRI mice 43 . Mice lacking the p21 gene product have a greater hyperplastic response and do not develop renal dysfunction or interstitial fibrosis after partial renal ablation. This protection may be related to a reduced amount of cell cycle arrest than that seen in normal mice with intact p21 (ref. 44) . Evidence for other G2/M arrest models comes from mice null for Stmn, encoding stathmin, which regulates the G2/M transition by being necessary for the proper formation of the mitotic spindle. These mice show delayed recovery, prolonged tubular proliferation and interstitial fibrosis after ischemic-reperfusion injury 45 . It is possible that normal nonfibrotic repair depends on efficient dedifferentiation of the surviving epithelial cells, which is dependent upon reduced p53-p21 pathway activation. If this pathway is activated, G2/M arrest occurs, reducing the efficiency of normal repair. It has recently been shown that the p53-p21 pathway is activated during the reprogramming of somatic cells to induced pluripotent stem cells, and inhibition of this pathway markedly improves dedifferentiation and greatly facilitates proliferation of the cells [46] [47] [48] .
In conclusion, the unique cell cycle data set from our current study, supported by our observations with PIF-α and contralateral nephrectomy after unilateral ischemia, indicate that G2/M arrest in proximal tubule cells after kidney injury results in abnormal amplification of profibrogenic factors. This serves as a mechanistic link between AKI and chronic progressive fibrotic kidney disease. Our data indicate that JNK, known to enhance TGF-β1 and CTGF gene transcription and promote fibrosis 49 , is activated during G2/M arrest and upregulates profibrotic gene expression in vitro and collagen production in vivo, whereas inhibition of JNK activity protects the kidney against the development of fibrosis. Maintaining the proper progression of tubular epithelial cells through the cell cycle during the injury phase is a potential therapeutic goal to prevent interstitial fibrosis and accelerated progression of chronic kidney disease. 
METHODS
Methods
